Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06430424

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Relapsed Cancer Astrocytoma Disease Attributes Glioblastoma Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale

Bordeaux, 33000, France

Location status: Recruiting

Location contact

Mathieu LARROQUETTE

CONTACT

[email protected]

About this study

Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months.

Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant.

The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age > 18 years
  • surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Exclusion criteria

  • systemic therapy received for non-glioblastoma tumor

Treatment and study plan

Relapsed glioblastoma

Biological

Paired tumor samples diagnosis/relapse

Primary outcomes

  1. Evaluation of metabolic changes involved in glioblastoma relapse

    Time frame: Up to 2 years after the start of the study

    Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample

Secondary outcomes

  1. Progression-free survival

    Time frame: From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

    Progression-free survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse measured at time of inclusion

  2. Overall survival

    Time frame: From date of the second surgery until the date of death from any cause, assessed up to 5 years

    Overall survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse

Study contacts

Contact information is provided by the study sponsor or research team.

Julien ENGELHARDT

CONTACT

[email protected]

Mathieu LARROQUETTE

CONTACT

[email protected]

+33 5 56 79 58 08

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.

Acronym: GBrecurr

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
May 28, 2024
Registry last updated
Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.